Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

doi:10.1101/mcs.a001677

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Cold Spring Harbor molecular case studies - 1 Jul 2017

Meißner Tobias, Mark Adam, Williams Casey, Berdel Wolfgang E, Wiebe Stephanie, Kerkhoff Andrea, Wardelmann Eva, Gaiser Timo, Müller-Tidow Carsten, Rosenstiel Philip, Arnold Norbert, Leyland-Jones Brian, Franke Andre, Stanulla Martin, Forster Michael

Abstract excerpt

A triple-negative breast cancer patient had no hereditary BRCA1, BRCA2, or TP53 risk variants. After exhaustion of standard treatments, she underwent experimental treatments and whole-exome sequencing of tumor, blood, and a metastasis. Well-tolerated experimental bortezomib monotherapy was administered for a progression-free period of 11 mo. After progression, treatments were changed and the exome data were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Disease-Free Survival

Share to Exome

Share to Exome Sequencing

Share to Germ-Line Mutation

Share to Glutathione S-Transferase pi

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28679691
DOI: 10.1101/mcs.a001677
PMCID: PMC5495034

Genes

BRCA1
BRCA2
CBR3
GSTP1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.PMID 28679691Read ↗

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity Read ↗

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Semantic proximity Read ↗

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.Semantic proximity Read ↗

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.Semantic proximity Read ↗

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.Semantic proximity Read ↗

Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution.Semantic proximity Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.Semantic proximity Read ↗

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast CancerSemantic proximity Read ↗

Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC modelsSemantic proximity Read ↗

Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up DateSemantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.